# Perioperative Management of Paraneoplastic Necrotizing Myopathy in Thyroidectomy: A Case Report

**Authors:** Tracy Wong

PMC · DOI: 10.7759/cureus.57351 · 2024-03-31

## TL;DR

A 63-year-old woman with paraneoplastic necrotizing myopathy underwent successful thyroidectomy with volatile anesthetics, showing no complications.

## Contribution

This case report provides evidence that volatile anesthetics can be safely used in paraneoplastic necrotizing myopathy patients.

## Key findings

- The patient tolerated sevoflurane and rocuronium without malignant hyperthermia or rhabdomyolysis.
- Postoperative neurological symptoms resolved completely within three months.
- Volatile anesthetics may be a viable option for PNM patients despite limited safety data.

## Abstract

Perioperative management of patients with myopathies can be challenging due to the increased risk of malignant hyperthermia (MH) and anesthesia-induced rhabdomyolysis (AIR). However, currently, there is no evidence regarding the optimal anesthetic management for paraneoplastic necrotizing myopathy (PNM) (total intravenous anesthetic vs. volatile anesthetics). Here, I report a case where anesthesia was administered safely using volatile anesthetics. A 63-year-old female presented with PNM associated with papillary thyroid carcinoma, necessitating urgent thyroidectomy. The patient, previously diagnosed with anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) antibody-associated myopathy, exhibited progressive weakness and dysphagia, prompting suspicion of PNM. The patient's compromised respiratory status, attributed to tracheal compression by a large goiter, necessitated an urgent thyroidectomy. Anesthetic management considerations included the potential effect of HMGCR-M on respiratory muscles and the need for careful planning to mitigate postoperative complications. The patient underwent total thyroidectomy, left central compartment clearance, and tracheostomy. The surgery proceeded uneventfully, with meticulous monitoring and adjustment of anesthetic agents to maintain hemodynamic stability. Postoperatively, the patient recovered well, demonstrating complete resolution of neurological symptoms during a three-month follow-up. The case underscores the importance of recognizing paraneoplastic syndromes in the context of thyroid surgery and highlights potential challenges faced by anesthesiologists. Despite the lack of established safety data for anesthetic drugs in HMGCR-M necrotizing myopathy, the case demonstrates the successful use of sevoflurane and rocuronium.

## Linked entities

- **Proteins:** HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase)
- **Chemicals:** sevoflurane (PubChem CID 5206), rocuronium (PubChem CID 441290)
- **Diseases:** papillary thyroid carcinoma (MONDO:0005075), malignant hyperthermia (MONDO:0018493)

## Full-text entities

- **Genes:** HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) [NCBI Gene 3156] {aka LDLCQ3, LGMDR28, MYPLG}
- **Diseases:** MH (MESH:D008305), thyroid (MESH:D013966), dysphagia (MESH:D003680), AIR (MESH:D012206), papillary thyroid carcinoma (MESH:D000077273), HMGCR-M (MESH:C538324), myopathies (MESH:D009135), weakness (MESH:D018908), goiter (MESH:D006042), PNM (MESH:D010257)
- **Chemicals:** sevoflurane (MESH:D000077149), rocuronium (MESH:D000077123)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11061826/full.md

---
Source: https://tomesphere.com/paper/PMC11061826